Form 4: OrbiMed Advisors Reports Enliven Therapeutics Stake

OrbiMed Advisors LLC, along with affiliated entities, has reported significant transactions and beneficial ownership changes related to Enliven Therapeutics, Inc. (ELVN).

Summary

• OrbiMed Advisors LLC, acting through its general partners OrbiMed Genesis GP LLC and OrbiMed Capital GP VII LLC, has filed a Form 4 detailing transactions and beneficial ownership of Enliven Therapeutics, Inc. (ELVN) common stock.
• The filing indicates transactions on June 22, 2026, involving the acquisition and disposition of common stock.
• OrbiMed Genesis Master Fund, L.P. holds a significant portion of the securities, with OrbiMed Genesis GP LLC as its general partner and OrbiMed Advisors LLC as the managing member.
• OrbiMed Private Investments VII, LP also holds securities, with OrbiMed Capital GP VII LLC as its general partner and OrbiMed Advisors LLC as the managing member.
• Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports on ownership changes and disclaimers, which are standard for institutional investors, without providing new performance data or strategic outlook.

Positives

• OrbiMed Advisors, a significant investment firm, continues to hold a substantial beneficial ownership in Enliven Therapeutics, Inc., indicating ongoing confidence in the company.
• The filing clearly outlines the structure of beneficial ownership, providing transparency to investors regarding the holdings of OrbiMed entities.

Negatives

• The filing details dispositions of securities, which could be interpreted as a reduction in direct holdings by certain OrbiMed entities, although overall beneficial ownership may remain significant.
• The complex ownership structure involving multiple funds and general partners can obscure the precise nature of control and beneficial interest for casual observers.

Risks

• The disclaimer of beneficial ownership by reporting persons, except to the extent of their pecuniary interest, introduces a degree of uncertainty regarding the ultimate control and economic interest in the securities.
• Potential for future sales or changes in beneficial ownership by OrbiMed entities could impact Enliven Therapeutics' stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Enliven Therapeutics' future performance. It solely reports on past transactions and beneficial ownership.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any.
• This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

StockSavvy.ai notes that Form 4 filings from major investment firms like OrbiMed Advisors are common in the biotechnology and pharmaceutical sectors, signaling significant investment and potential shifts in holdings. Such filings are crucial for understanding the influence of key institutional investors.

Related Party Transactions

• The filing details the relationships between OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, OrbiMed Capital GP VII LLC, OrbiMed Genesis Master Fund, L.P., and OrbiMed Private Investments VII, LP, which constitute related party structures for beneficial ownership reporting.

Stakeholder Impact

• Shareholders: The reported transactions and ownership structure provide transparency into the holdings of a major investor, which can influence market perception and trading activity.
• Management: The filing clarifies the beneficial ownership landscape, which is a key aspect of corporate governance.
• Creditors: While not directly impacted, significant shifts in major shareholder positions can indirectly affect investor confidence in the company's stability.

Next Steps

• Continued monitoring of future Form 4 filings from OrbiMed Advisors and other significant shareholders for further changes in beneficial ownership.
• Analysis of Enliven Therapeutics' subsequent financial reports and strategic announcements to understand the company's performance and outlook.

Key Dates

Keywords

Form 4, SEC Filing, OrbiMed Advisors, Enliven Therapeutics, ELVN, Beneficial Ownership, Securities Transaction, Investment Management, Venture Capital